Serological tests for visceral leishmaniasis. by Lockwood, Diana NJ & Sundar, Shyam
Lockwood, DNJ; Sundar, S (2006) Serological tests for visceral leish-
maniasis - Have high sensitivity, but several limitations. BMJ, 333
(7571). pp. 711-2. ISSN 1468-5833 DOI: 10.1136/bmj.38989.567083.BE
Downloaded from: http://researchonline.lshtm.ac.uk/10618/
DOI: 10.1136/bmj.38989.567083.BE
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution Non-commercial
http://creativecommons.org/licenses/by-nc/2.5/
Serological tests for visceral leishmaniasis
Have high sensitivity, but several limitations
Visceral leishmaniasis is a parasitic diseasetransmitted by sandflies, with 0.5 million newcases annually.1 It is most commonly seen in
India, Bangladesh, Brazil, Sudan, and around the
Mediterranean. About two cases are seen each year in
the United Kingdom, and these usually originate from
around the Mediterranean.2
Patients with visceral leishmaniasis present with
fever, splenomegaly, and weight loss. It can be difficult
to diagnose this disease in endemic settings as several
causes of febrile splenomegaly exist, notably malaria.
In this week’s BMJ, a meta-analysis by Chappuis and
colleagues compares the diagnostic performance of
two serological tests in endemic settings, the direct
agglutination test (DAT) and rK39 dipstick test.3
Outside endemic areas visceral leishmaniasis is often
only considered after haematological malignancies
have been excluded.2
In immunocompetent people visceral leishmania-
sis can be treated with a 28 day course of a pentavalent
antimonial, and the cure rate is 90-95%.4 In resource
rich settings patients are treated with six to 10 days of
liposomal amphotericin (an antifungal agent), and the
cure rate is higher at 95-98%.4
The gold standard for diagnosis of visceral
leishmaniasis is to identify parasites in smears of tissue
aspirates (spleen, bone marrow, or lymph node).
Splenic smears have a sensitivity of > 90%, but the
procedure carries a small risk of intra-abdominal
haemorrhage.5 Bone marrow aspiration is often done
but is painful and less sensitive.
In endemic settings the resources needed to
support tissue diagnosis—skilled technicians, good
smears, proper stains, appropriately maintained and
working microscopes—are often unavailable.5 Serologi-
cal diagnosis is safer and two field tests have been
developed, DAT and the Ks30 dipstick test.
DAT measures anti-leishmania antibody titres
using a freeze dried antigen.6–8 However, it requires test
readings to be standardised, prolonged incubation, and
the handling of multiple samples. In Sudan, DAT test-
ing is done in field laboratories on filter paper blood
samples. Médecins sans Frontières has developed a
management strategy based on DAT titres in which
patients with a titre of 1:6400 are treated, and those
with titres between 1:400 and 1:6400 have a splenic
aspirate. About 10% of suspected cases will need
splenic aspirates. The K39 dipstick test is highly specific
for visceral leishmaniasis and detects antibodies to a
specific 39 amino acid sequence (K39). It has been
developed as an immunochromatographic strip test
dipstick.9 The test is easy to perform—a village health
worker can be trained in few hours—the kit can be
stored at ambient temperature, no equipment is
needed, and it can be carried to remote areas.
A meta-analysis published in this week’s BMJ
evaluated the performance of both serological tests.3
Only studies with the gold standard of parasites seen on
splenic aspirate were included, and data from 30 studies
on the DAT test and 13 on the K39 dipstick test were
analysed. The combined data set relates to 2817 patients
with visceral leishmaniasis and 6552 controls. Both tests
have high sensitivities, 94.8% for DAT and 93.9% for the
K39 test. The authors were rigorous and calculated
separate specificities when controls were patients with
clinically suspected disease or healthy people; even so
the overall specificities were 85.9% and 90.6%,
respectively. This confirms that both tests performed
well and either could be incorporated into national
guidelines for diagnosing visceral leishmaniasis. There
are interesting regional differences—the tests are more
sensitive in South Asia than in Sudan—perhaps because
Sudanese patients produce lower antibody titres. This
highlights the importance of validating new diagnostic
tests in endemic areas even though this is costly. Visceral
leishmaniasis is an important coinfection in HIV
positive people, particularly in areas where highly active
antiretroviral therapy is not available, and this meta-
analysis only considered data from HIV negative
patients. Serology may be negative in up to half of HIV
positive patients coinfected with visceral leishmania-
sis.1 10 Such coinfections will become common in
endemic regions, and studies on the performance of the
tests in this group are needed.
Both serological tests can remain positive for
several years after cure and so cannot be used to detect
relapse or reinfection. Furthermore, in areas with high
transmission of visceral leishmaniasis, many people
will be infected but only a minority will develop clinical
illness. People who carry the infection test positive
serologically and sometimes form up to 32% of the
healthy population.8 11 Tests are therefore needed that
identify only active disease. A limitation of the dipstick
test is that it is only positive or negative and the titre
based screening strategy used by Médecins sans
Frontières cannot be applied.
Other tests are being developed. The latex aggluti-
nation test (KAtex) detects a leishmanial antigen in
boiled urine that disappears after cure. It has been
tested in Asia and Africa, and specificity has ranged
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from 47% to 95%12 13; it may be developed as an immu-
nochromatographic strip test for use with unboiled
urine. Another potential test detects erythrocyte sialic
acid, which is positive in patients with active disease but
becomes negative after cure.14 The test warrants further
clinical evaluation.
The World Health Organization could help in
ensuring that these tests remain available for the people
who need them. Two manufacturers have already
stopped producing dipsticks (Arista Biological and
Amrad). Academic studies are needed for evaluation,
and public health action is needed to incorporate good
tests into national policies while recognising the
commercial needs of manufacturers. Progress in
neglected diseases like leishmaniasis is often hampered
by lack of commitment from industry, and diagnostics
and drugs are abandoned when profits are insufficient.
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Combining aspirin with antithrombotic agents
Risk of bleeding is increased but can be minimised
The use of aspirin and other antiplatelet agentshas sky rocketed in the past decade as the indi-cations have widened to include primary and
secondary prevention of myocardial and cerebrovascu-
lar ischaemia. In the United States, an estimated 34.8%
of men and 26.2% of women over 40 years use aspirin
every day or on alternate days.1 Half of these patients
are classified as at high risk of cardiovascular disease.
With the development of safer antiplatelet agents such
as thienopyridines and the publication of major
randomised studies, the combination of aspirin and
clopidogrel has become a class I recommendation
(that is, it is considered to be beneficial, useful, and
effective) after percutaneous coronary interventions
with stenting in the US and in Europe.2 3 Combined
antithrombotic therapy is recommended for up to 12
months “in patients who are not at high risk of bleed-
ing.”2 The problem for clinicians is to balance the
benefits of combined antiplatelet therapy with the
potentially increased risk of gastrointestinal bleeding.
In this week’s BMJ a case control study by Hallas and
colleagues goes some way to measuring this risk.4
Aspirin is widely known to cause mucosal
ulceration that can lead to upper gastrointestinal
bleeding. Lower doses and slow release formulations of
aspirin have been used in the hope that they carry a
reduced risk of bleeding. In a meta-analysis of almost
66 000 people, Derry and colleagues found no relation
between gastrointestinal bleeding and aspirin dose or
formulation.5 They also showed that risk of bleeding
was not lower with prolonged use of aspirin, so the
notion of mucosal tolerance to aspirin remains a myth.
These findings were confirmed in a later study from
Spain, which focused on patients taking low dose aspi-
rin to prevent cardiovascular diseases.6
Clopidogrel has been recommended as the
treatment of choice for patients with coronary heart
disease who cannot tolerate aspirin.7 This is based pri-
marily on the CAPRIE study, which compared the effi-
cacy of clopidogrel with aspirin in preventing
myocardial ischaemia.8 Gastrointestinal bleeding was
reported in 1.99% of patients taking clopidogrel and
2.66% of those taking aspirin (p = 0.05). It has been
shown repeatedly that combining aspirin with clopi-
dogrel increases the risk of gastrointestinal bleeding
compared with using aspirin9 or clopidogrel alone.10
Hallas and colleagues found that upper gastro-
intestinal bleeding was associated with the use of low
dose aspirin, dipyridamole, and vitamin K antagonists
but not with clopidogrel.4 The finding that clopidogrel
did not increase bleeding risk contradicts other
reports.11 This discrepancy could be related to the rela-
tively small sample size of the current study (only 1443
participants, with 30 cases of bleeding). Importantly,
the authors found that combining aspirin with any of
the antithrombotic agents (clopidogrel, dipyridamole,
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